ClinicalTrials.Veeva

Menu
R

Red Maple Trials | Clinical Team

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

RPT193
REGN1908-1909

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix®
Biological: Influsplit®

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to re...

Enrolling
Allergic Conjunctivitis
Drug: Placebo
Drug: REGN1909

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urtica...

Enrolling
Chronic Spontaneous Urticaria
Drug: Placebo
Drug: Oral EP262

VBI-2901a is an investigational vaccine candidate that uses enveloped virus-like particles (eVLPs) to express the spike proteins of three coronavirus...

Active, not recruiting
COVID-19
Coronavirus Infections
Biological: VBI-2901a

Trial sponsors

Moderna logo
Regeneron Pharmaceuticals logo
V
E
RAPT Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems